A notable example of clinically-approved targeted therapy is bevacizumab, a vascular endothelial growth factor receptors (VEGFR) inhibitor, approved by the U.S. Food and Drug Administration (FDA) for treatment of progressive recurrent GBM [12]. Here, KDR is linked to glioblastoma.